(Reuters) -German vaccine maker BioNTech said on Tuesday that it plans to expand its investment in the United Kingdom by up ...

German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an ...

The FDA had given Pfizer and Moderna until May 17 to propose changes to the labels of their COVID-19 vaccines or challenge ...

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

BioNTech will invest up to £1bn in UK life sciences over 10 years, launching new AI and R&D centres in London and Cambridge.

Hundreds of highly skilled jobs will be created, and new research centres will be set up aimed at making new advances in ...

The FDA has told vaccine manufacturers to expand the warning labels on their COVID-19 shots with more information about the ...

The US Food and Drug Administration will now require Covid-19 vaccines from Pfizer/BioNTech and Moderna to use expanded ...

Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...

BioNTech said it plans to invest up to 1 billion pounds ($1.34 billion) over the next 10 years to expand its research and development activities for innovative medicines in the U.K.

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.